Hematologic effects and coagulopathy

Cardiopulmonary Bypass: Principles and Practice: Third Edition

Volumn , Issue , 2012, Pages 439-458

  Rinder, Christine S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650384558     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (118)

1. Almony GT, Lefkovits JK, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996;19:357-365.
2. Davie EW, OD R. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
3. MacFarlane R. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964;202:498-499.
4. Hoffman M, Monroe D. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
5. Hoffman M. A cell-based model of coagulation and the role of factor Vila. Blood Rev 2003;17:S1-S5.
6. Mann KG, Bummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-1515.
7. Bouchard B, Catcher C, Thrash B, et al. Effector cell protease receptor-1, a platelet activation-dependent membrane protein regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 1997;272:9244-9251.
8. Cawthern K, Veer Cvt, Lock J, et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998;91:4581-4892.
9. Walsh P. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001;86:75-82.
10. Baird TR, Walsh PN. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation. J Biol Chem 2002;277:38462-38467.
11. van't Veer C, KG M. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin III, and heparin cofactor-II. J Biol Chem 1997;272:4367-4377.
12. Osterud B, Bajaj MS, Bajaj SB. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995;73:873-875.
13. Butenas S, Branda RF, van't Veer C, et al. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001;86:551-554.
14. Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding:role of anaemia and beneficial effect of red cell transfusions. Lancet 1982;2:1013-1015.
15. Hartwig J. Platelet structure. In:Michelson A, ed. Platelets, 1st ed. Amsterdam:Academic Press, 2002:37-52.
16. Kulkarni S, Dopheide SM, Yalp CL, et al. A revised model of platelet aggregation. J Clin Invest 2000;105:783-791.
17. Kovacsovics T, Hartwig J. Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation. Blood 1996;87:618-629.
18. Shattil, S, Hoxie, J, Cunningham, M, et al. Changes in platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985;260:11107-11114.
19. Burrige K, Fath K. Focal contacts:transmembrane links between the extracellular matrix and the cytoskeleton. Bioessays 1989;10:104-108.
20. de Wit TR, Mourik JV. Biosynthesis, processing and secretion of von Willebrand factor:biological implication. Best Pract Res Clin Haematol 2001;14:241-255.
21. Savage B, Ruggeri Z. Platelet thrombus in flowing blood. In:Michelson A, ed. Platelets, 1st ed. Amsterdam:Academic Press, 2002:215-228.
22. Frerickson BJ, Dong JF, McIntire LV, et al. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998;92:3684-3693.
23. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in whole blood. Blood 1999;94:172-178.
24. Lopez J, Andrews R, Afshar-Kharghan V, et al. Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
25. Plow EF, Shattil SJ. Integrin aIIbb3and platelet aggregation. In:Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and thrombosis:basic principles and clinical practice. Philadelphia:Lippincott Williams & Wilkins, 2001:479-491.
26. Goto S, Ikeda Y, Saldivar E, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101:385-392.
27. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389.
28. Scott EM, Ariens R, Grant PJ. Genetic and environmental determinants of fibrin structure and function:relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004;24:1558-1566.
29. Ariens R, Lai TS, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002;100:743-754.
30. Faust SN, Heyderman RS. Coagulation in severe sepsis:a central role for thrombomodulin and activated protein C. Crit Care Med 2001;29:S62-SS8.
31. Esmon C. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29:S48-S52.
32. Camire RM, Kalafatis M, Simioni P, et al. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 1998;91:2818-2829.
33. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997;99:1351-1360.
34. Tsai H, Sussman I, Nagel R. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994;83:2171-2179.
35. Tsai H. Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003;23:388-396.
36. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005;25:2470-2479.
37. Gurewich V, Emmons F, Pannell R. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators:demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 1988;2:143-149.
38. Dellas C, Loskutoff DJ. Historical anaysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005;93:631-640.
39. Nesheim M. Thrombin and fibrinolysis. Chest 2003;124:33S-39S.
40. Brummel-Ziedins K, Vossen CY, Rosendaal FR, et al. The plasma hemostatic proteome:thrombin generation in healthy individuals. J Thromb Haemost 2005;3:1472-1481.
41. Allen GA, Wolberg AS, Oliver JA, et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004;2:402-413.
42. Summer WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996;81:533-543.
43. Vanschoonbeek K, Feijge MAH, van Kampen JW, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma:subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2002;2:476-484.
44. Courtney JM, Forbes CD. Thrombosis on foreign surfaces. Br Med Bull 1994;50:966-981.
45. Fujimura Y, Titani K, Holland L, et al. A heparin-binding domain of human von Willebrand factor. J Biol Chem 1987;262:1734-1739.
46. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1878-1893.
47. Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001;93:20-27.
48. Chandler WL. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2004;19:459-467.
49. Davidson SJ, Burman JF, Philips SM, et al. Correlation between thrombin potential and bleeding after cardiac surgery in adults. Blood Coagul Fibrinolysis 2003;14:175-177.
50. Wolberg AS, Meng ZH, Monroe DM, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004;56:1221-1228.
51. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma:effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma 1998;44:864-854.
52. Colman RW, Schmaier AH. Contact system:a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997;90:3819-3843.
53. Wachtfogel YT, HarpelPC, Edmunds LH Jr, etal. Formation of C1s- C1 inhibitor, kallikrein-C1 inhibitor, and plasmin-alpha-2-plasmin inhibitor complexes during CPB. Blood 1989;73:468-471.
54. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass:the importance of lung exclusion. Chest 2001;120:1776-1782.
55. Chung JH, Gikakis N, Rao AK, et al. Pericardial blood activates the extrinsic pathway during clinical cardiopulmonary bypass. Circulation 1996;96:3534-3541.
56. Sturk-Maquelin KN, Nieuwland R, Romijn M, et al. Pro- and noncoagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003;1:1920-1926.
57. Boisclair MD, Lane DA, Phillippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-3357.
58. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003;101:4355-4362.
59. Dixon B, Santamaria J, Campbell D. Coagulation activation and organ dysfunction following cardiac surgery. Chest 2005;128:229-236.
60. Beurling-Harbury C, Galvan CA. Acquired decrease in platelet secretory ADP associated with increased bleeding in postcardiopulmonary bypass patients and patients with severe valvular heart disease. Blood 1978;52:13-23.
61. Friedenberg WR, Myers WO, Plotka ED, et al. Platelet dysfunction associated with cardiopulmonary bypass. Ann Thorac Surg 1978;25:298-305.
62. Slaughter TF, Sreeram G, Sharma AD, et al. Reversible shear- mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 2001;12:85-93.
63. McKenna T, Bachman F, Whittaker B, et al. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet function during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-307.
64. Holloway DS, Summarie L, Sandesara J, et al. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988;59:62-67.
65. Harker LA, Malpass TW, Branson HE, et al. Mechanisms of abnormal bleeding in patients undergoing CPB:acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-834.
66. Addonizio VP Jr, Strauss JF III, Colman RW, et al. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with a bubble oxygenator. J Thorac Cardiovasc Surg 1980;79:91-96.
67. Addonizio VP Jr, Strauss JF III, Colman RW, et al. Effects of prostaglandin E1 on platelet loss during in vivo and in vitro extracorporeal circulation with a bubble oxygenator. J Thorac Cardiovasc Surg 1979;77:119-126.
68. Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-1205.
69. Zill P, Fasol R, Broscurth P, et al. Blood platelets in CPB operations. Recovery occurs after initial stimulation rather than continual activation. J Thorac Cardiovasc Surg 1989;97:379.
70. Addonizio VP Jr. Platelet function in cardiopulmonary bypass and artificial organs. Hematol Oncol Clin North Am 1990;4:145-155.
71. Addonizio VP, Macarak J, Nicolaou KC, et al. Effects of prostacyclin and albumin on platelet loss during in vitro simulation of extracorporeal circulation. J Lab Clin Med 1985;105:514-522.
72. Addonizio VP Jr, Fisher CA, Jenkin BK, et al. Iloprost, a stable analogue of prostacyclin, preserves platelet during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 1985;89:926-933.
73. Chung A, Wildhirt SM, Wang S, et al. Combines administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction:a pilot clinical study. J Thorac Cardiovasc Surg 2005;129:782-790.
74. Musial J, Rucinski B, Williams JA, et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuit by disintegrins:RGD- containing peptides from viper venoms. Circulation 1990;82:261-273.
75. Rinder CS, Bonert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-393.
76. Rosing J, van Rijn JL, Bevers EM, et al. The role of activated human platelets in prothrombin and factor X activation. Blood 1985;65:319-332.
77. Szasz R, Dalte GL. COAT platelets. Curr Opin Hematol 2003;10:351-355.
78. Rinder HM, Tracey JB, Techt M, et al. Differences in platelet granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost 1998;80:457-462.
79. Thompson CB, Eaton KA, Princiotta SM, et al. Size-dependent platelet subpopulations:relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982;50:509-519.
80. Laufer N, Merin G, Grover NB, et al. This influence of cardiopulmonary bypass on the size of human platelets. J Thorac Cardiovasc Surg 1975;104:727-731.
81. Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after CPB and their relationship to bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992;104:94-107.
82. Gant JA, Scrutton MC. Positive interactions between agonists in the aggregation response of human blood platelets:interaction between ADP, adrenaline and vasopressin. BrJ Haematol 1980;44:109-115.
83. Wachtfogel YT, Musial J, Jenkin V, et al. Loss of platelet alpha 2-adrenergic receptors during simulated extracorporeal circulation:prevention with prostaglandin E;. J Lab Clin Med 1985;105:601-622.
84. Musial J, Niewiarowski S, Hershock D, et al. Loss of fibrinogen receptors from the platelet surface during simulated circulation. JLab Clin Med 1985;105:514-522.
85. Wenger RK, Lukasiewicz H, Mikuta BS, et al. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;97:235-239.
86. Rinder CS, Mathew JP, Rinder HM, et al. Modulation of platelet surface adhesion receptors during CPB. Anesthesiology 1991;75:563-570.
87. Mascelli MA, Worley S, Veriabo N, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 1997;96:3860-3866.
88. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIa and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001;12:101-108.
89. Greilich PE, Carr ME Jr, Carr SL, et al. Reductions in platelet force development by CPB are associated with hemorrhage. Anesth Analg 1995;80:459-464.
90. Carr ME Jr, Martin EJ, Carr SL. Delayed, reduced, or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul Fibrinolysis 2002;13:193-197.
91. Boyle EM Jr, Pohlman TH, Johnson MC, et al. Endothelial cell injury in cardiovascular surgery:the systemic inflammatory response. Ann Thorac Surg 1997;63:277-284.
92. Stibbe J, Kluft C, Brommer E, et al. Enhanced fibrinolytic activity during CPB in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984;14:375-382.
93. Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 during cardiopulmonary bypass. Thromb Res 2003;112:185-192.
94. Chandler WL, Velan T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis 2004;15:583-591.
95. Niewiarowski S, Senui AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. J Clin Invest 1973;51:1647-1659.
96. Schafer A, Levine Konkle B, et al. Thrombotic disorders:diagnosis and treatment. In:Hematology (The American Society of Hematology Education Program). 2003;520-539. http://www .asheducationbook.hematologylibrary.org/cgi/reprint/2003/1/520. Accessed June, 2007.
97. Soslau G, Horrow JC, Parker J, et al. The effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991;38:113-119.
98. Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations:platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460-1466.
99. Adelman B, Michelson AD, Loscalzo J, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985;65:32-40.
100. George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoproteins:studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory syndrome and cardiac surgery. JClin Invest 1986;78:340-348.
101. Van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-797.
102. Dunlop LC, Andrews TK, Lopez J, et al. Congenital platelet adhesion defects:Bernard-Soulier syndrome. In:Loscalzo J, AI S, eds. Thrombosis and hemorrhage. Baltimore:Lippincott Williams & Wilkins, 1998:685-689.
103. Rinder CS, Gaal D, Student L, et al. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;107:280-288.
104. Perutelli P. Proteolysis of von Willebrand factor is increased during cardiopulmonary bypass. Thromb Res 2001;102:467-473.
105. Morgan BP. Complement membrane attack on nucleated cells:resistance, recovery, and non-lethal effects. Biochem J 1989;264:1-14.
106. Chenowith DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass:evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;81:370-377.
107. Haslam P, Townsend P, Branthwaite M. Complement activation during cardiopulmonary bypass. Anaesthesia 1980;25:22-26.
108. Cavarocchi NC, Schaff HV, Orszulak TA, et al. Evidence for complement activation by protamine-heparin interaction after CPB. Surgery 1985;98:525-530.
109. Fletcher MP, Stahl G, Longhurst J. C5a-induced myocardial ischemia:role for CD18-dependent PMN localization and PMN- platelet interactions. Am J Physiol 1993;265:H1750-H1761.
110. Hattori R, Hamilton KK, Fugate RD, et al. Complement proteins C5b-9 induce secretion of high-molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-9060.
111. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-1572.
112. Rinder CS, Rinder HM, Johnson K, et al. Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation 1999;100:553-558.
113. Wiedmer T, Esmon C, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through the platelet prothrombinase. Blood 1986;68:875-880.
114. Ando B, Wiedmer T, Sims PJ. The secretory release reaction initiated by complement proteins C5b-9 occurs without platelet aggregation through glycoprotein IIb-IIIa. Blood 1989;73:462-467.
115. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:552-559.
116. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003;89:610-621.
117. Plow EF. The major fibrinolytic proteases of human leukocytes. Biochim Biophys Acta 1980;630:47-56.
118. Despotis GJ, Levine V, Goodnough LT. Relationship between leukocyte count and patient risk for excessive blood loss after cardiac surgery. Crit Care Med 1997;25:1338-1346.